‘What Do You Have to Lose?’: What We Heard This Week

Allergies & Asthma

“If you have something that is potentially beneficial, safe, and cheap, what do you have to lose?” — Paul Marik, MD, of Eastern Virginia Medical School, on quercetin’s potential place in COVID-19 treatment.

“There’s a lot of thanks from the community when we do autopsies.” — Sharon Fox, MD, of Louisiana State University in New Orleans, commenting on clinical autopsy rates being higher in Black patients than white patients.

“And yet despite being in the epicenter of the epicenter, the pandemic passed us and we were only able to get few patients into our randomized trials.” — Alex Spyropoulos, MD, of Northwell Health’s Feinstein Institutes for Medical Research in New York, on delayed and disrupted COVID-19 trials.

“The brain, although generally well protected, is far from immune from the effects of this virus.” — Edwin van Beek, MD, PhD, of the University of Edinburgh, commenting on a seven times higher stroke rate in hospitalized patients with COVID-19 than with respiratory flu.

“On the whole, our findings are reassuring.” — Kathryn Mansfield, PhD, and Sinéad Langan, PhD, both of the London School of Hygiene and Tropical Medicine, discussing their study findings on cancer risk in atopic eczema patients.

“There clearly is something going on that protects women.” — Michael Nimaroff, MD, director of obstetrics and gynecology at Northwell Health in New York, on the biological protections of female sex hormones against COVID-19.

“The findings suggest that cognitive health in old age depends in part on cognitive development in early life.” — Shahram Oveisgharan, MD, of Rush University in Chicago, discussing research showing cognitive enrichment in childhood was tied to lower levels of Alzheimer’s pathology change and slower late-life cognitive decline.

Leave a Reply

Your email address will not be published. Required fields are marked *